Energy metabolism regulators effect on clinical course and inflammatory markers in patients with exacerbation of severe copd

We assessed in a prospective, randomised, placebo-controlled trial the effects of «yantar-antitox» in patients with exacerbations of COPD requiring hospital admission. We recruited patients with exacerbations of severe COPD who were randomly assigned oral «Yantar-antitox» (n=33) or identical placebo...

Full description

Bibliographic Details
Main Authors: M. S. Sanzharovskaya, N. V. Varvyanskaya, N. S. Yamkina, I. N. Pechyorkina, A. A. Smotrova, S. I. Antipov, Ye. P. Roslyakova, O. Ye. Akbasheva, O. P. Sanzharovskaya, V. A. Khazanov, G. E. Chernogoryuk
Format: Article
Language:English
Published: Siberian State Medical University (Tomsk) 2008-09-01
Series:Бюллетень сибирской медицины
Subjects:
Online Access:https://bulletin.ssmu.ru/jour/article/view/3504
Description
Summary:We assessed in a prospective, randomised, placebo-controlled trial the effects of «yantar-antitox» in patients with exacerbations of COPD requiring hospital admission. We recruited patients with exacerbations of severe COPD who were randomly assigned oral «Yantar-antitox» (n=33) or identical placebo (n=45) for 14 days, in addition to standard treatment with nebulised bronchodilators, antibiotics, and oxygen. We did spirometry and recorded symptom scores in inpatients. The 6-min walking distance (6MWD) was also determined. Inflammatory markers were measured in induced sputum and serum. Significant increase in the percentage predicted lung vital capacity, maximal expiratory flow volume, 6MWD were found between the patient in the «Yantar-antitox» — treated group.
ISSN:1682-0363
1819-3684